Communication from the pharmaceutical industry to the medical profession (and to the patient) has evolved considerably in the last two decades. The advent of digital has obviously been at the heart of this (r)evolution, facilitating or making it possible, but it is only one aspect of it. True fund trends, echoing equally important societal trends, affect how Big Pharma communicates. But that's not all ! Health-related issues (increasing interest in the patient as such, the growing importance of chronic diseases), R&D techniques (the advent of Big Data, personalized treatments), and other aspects contribute to this revolution.
But while the offer has changed significantly, the doctor's request has also greatly changed, much more demanding on the content he seeks, willingly swinging between different contents, and looking for “efficiency”. Pharmaceutical companies and other stakeholders are not left out. Between "supply" and "demand", between "promotion" and "education", a world is changing ... The third edition of this Digital Pharma summit will feature this.